Mean body weight decreases were greater with all dapagliflozin doses than with placebo, although they did not reach statistical significance (Fig. 3 C , Table 2 ).
← all excerpts
Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.
1
—
—